New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
11:05 EDTCI, AZNCigna, AstraZeneca in Crestor pact
Cigna (CI) has entered into a first-of-its-kind contract with AstraZeneca (AZN) to help ensure that customers are given an appropriate cholesterol-lowering medication based on their treatment needs. For Cigna customers who are at increased risk for atherosclerotic cardiovascular disease, ASCVD, and need to aggressively manage their low-density lipoprotein cholesterol, LDL-C, CRESTOR , a brand-name, cholesterol-lowering drug manufactured by AstraZeneca, can be prescribed and filled without requiring prior authorization. “Our arrangement with Cigna is an evolutionary step in supporting patient health, and facilitating access to CRESTOR for high risk patients. Predictive risk modeling can be used to help support the right treatment for the right patient at the right time, and we are excited to be working with Cigna because they are the only insurance carrier or Pharmacy Benefit Manager we have seen who has offered this capability,” says Philip de Vane, MD, Executive Director of US Medical Affairs, AstraZeneca.
News For AZN;CI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
15:18 EDTAZNAstraZeneca confirms FDA approval of LYNPARZA
Subscribe for More Information
12:12 EDTAZNMyriad Genetics receives FDA approval of BRACAnalysis CDx
Myriad Genetics (MYGN) announced that it has received approval from the U.S. FDA for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca's (AZN) drug Lynparza. Lynparza is the first poly ADP-ribose polymerase inhibitor for patients with germline mutations in BRCA1/2 advanced ovarian cancer who have had three or more lines of chemotherapy. BRACAnalysis CDx is Myriad's first FDA-approved companion diagnostic for use with a novel PARP inhibitor. BRACAnalysis CDx is a highly accurate molecular companion diagnostic test that identifies deleterious or suspected deleterious mutations in the BRCA1 and BRCA2 genes, using DNA obtained from a blood sample. BRACAnalysis CDx was proven in clinical studies to effectively identify patients with BRCA mutations who would be candidates for Lynparza. The approval of BRACAnalysis CDx demonstrates Myriad's commitment to developing companion diagnostics and is the culmination of an intensive, multiyear scientific collaboration with AstraZeneca to advance personalized medicine for women with ovarian cancer.
11:45 EDTAZNFDA approves Lynparza to treat advanced ovarian cancer
The U.S. FDA granted accelerated approval to Lynparza, a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test. Lynparza is marketed by AstraZeneca Pharmaceuticals, based in Wilmington, Delaware. Reference Link
December 17, 2014
10:51 EDTCILeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Gupte provides outlook and favorite names for 2015 in the Hospitals and Managed Care Industry on an Analyst/Industry conference call to be held on December 18 at 1 pm.
December 15, 2014
07:33 EDTAZNAdvaxis announces FDA acceptance of INDA to commence clinical trials of ADXS-HPV
Subscribe for More Information
December 11, 2014
16:03 EDTAZNAmgen, AstraZeneca to present results from Phase 3 plaque psoriasis study
Subscribe for More Information
07:28 EDTAZNCBI to hold a summit
2nd Specialty Data Optimization Summit is being held in Philadelphia on December 11.
December 10, 2014
14:45 EDTCIDeal would block payments to health insurance companies, The Hill says
Subscribe for More Information
December 9, 2014
09:10 EDTAZNARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
08:02 EDTAZNMoventig approved in EU for opioid-induced constipation
Nektar (NKTR) reported partner AstraZeneca (AZN) announced that MOVENTIG has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative. MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist to be approved in the European Union.
07:44 EDTAZNAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
December 8, 2014
07:05 EDTAZNInnocoll appoints Tony Zook as CEO
Innocoll AG (INNL) announced that Tony Zook, formerly executive vice president, Global Commercial Operations, at AstraZeneca (AZN), has been appointed CEO effectively immediately. Michael Myers, will continue with the company as head of Portfolio Operations.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use